News and Trends 21 Sep 2022 New Bio Studio program collaboration looks to create life science start-ups The BioInnovation Institute (BII), has entered a collaboration with Imperial College London in the U.K. to launch a new translational project under its Bio Studio program. The program aims to foster the creation of new life science start-ups based on research to benefit people and society. Based in Denmark, the BII is an international commercial, […] September 21, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 Positive results from Arecor Therapeutics’ clinical trial of rapid, concentrated insulin Arecor Therapeutics today (September 20) announced positive results from a phase 1 clinical trial of its rapid, concentrated insulin product. The company’s candidate named AT278 is formulated using its Arestat technology and designed to significantly accelerate insulin absorption post injection. This is to enable more effective and convenient management of blood glucose levels in people […] September 20, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 20 Sep 2022 CGT Catapult begins VR training to help ensure future workforce needs A first-of-its-kind pilot to provide augmented reality (AR) and virtual reality (VR) training to develop the knowledge and skills needed for a career in advanced therapy medicinal product (ATMP) development has been launched. The training will be done by the Cell and Gene Therapy Catapult (CGT Catapult), in partnership with the University of Sheffield Advanced […] September 20, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 Domainex’ drug shows positive data for treatment of interferonopathies Interferonapathies such as lupus, Sjögren’s syndrome, and scleroderma could be treated effectively after positive human ex-vivo data was produced. Domainex Ltd., carried out an in-house research program to identify inhibitors of protein kinases TBK1 and IKK-epsilon and DMXD-011 has been nominated as a preclinical drug candidate. The molecule is orally-bioavailable and highly selective. Disease modifying The […] September 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Sep 2022 CHMP recommends approval of Beyfortus for prevention of RSV disease in infants Beyfortus, which is being developed jointly by Sanofi and AstraZeneca, is a step closer to preventing respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and infants. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Beyfortus (nirsevimab) for the prevention of RSV lower respiratory […] September 16, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
In Depth 14 Sep 2022 Rivaling the Golden Triangle at Bristol’s Science Creates hub The Golden Triangle region hosts much of the U.K.’s biotech innovation. However, there are many hubs emerging across the nation, with Bristol’s Science Creates network being one thriving example. The U.K. hosts one of Europe’s leading biotech industries in terms of startup formation, scientific publications and investments. “The U.K. punches well above its weight with […] September 14, 2022 - 9 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Tumors destroyed in five types of cancer by cell therapy from LIfT BioSciences LIfT BioSciences announced today (September 14) that its cell therapy has shown tumor destruction across five different solid tumor types in tumoroid models. The N-LIfT cell therapy destroyed on average more than 90% of the tumoroid in a PDX organoid across five of the most challenging to treat solid tumor types. A PDX organoid is […] September 14, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 New study reveals first genetic links in ME and chronic fatigue syndrome For the first time in more than 30 years, replicable genetic findings have been reported in the study into myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). UK-based PrecisionLife today (September 14) unveiled the results offering new approaches for better diagnosis and treatments of patients. The data has also been submitted for peer reviewed publication and is available […] September 14, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 13 Sep 2022 Arpeggio Biosciences raises $17M in Series A funding to support drug pipeline Arpeggio Biosciences has raised $17 million in series A funding in a round led by Builders VC. Support for the U.S.-based preclinical therapeutics company making technology targeting transcriptional dysregulation in disease, also came from its seed round investors. These include Khosla Ventures, TechU Ventures, FundersClub, Alice Zhang, and Fifty Years, as well as new participants […] September 13, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
Interview 12 Sep 2022 Orchestrating the evolving cell therapy supply chain In a few decades, the cell and gene therapy sector has diversified into many complex technologies. Paul Viggers, chief commercial officer at the U.K. firm TrakCel, explains how the company’s platform can tackle the intricacies of developing cell and gene therapies. After cell and gene therapy funding smashed records in 2021, the emerging sector has […] September 12, 2022 - 5 minutesmins - By Jonathan Smith Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Ayala Pharmaceuticals presents interim data on desmoid tumor trial Clinical oncology company Ayala Pharmaceuticals, Inc. has announced updated, positive interim results from part A of its ongoing RINGSIDE pivotal phase 2/3 clinical trial evaluating investigational new drug AL102 in desmoid tumors. Ayala Pharmaceutical’s AL102 is a selective, oral gamma-secretase inhibitor. The data are being featured in an oral presentation at the European Society for […] September 12, 2022 - 4 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 12 Sep 2022 Cuffless device worn 24/7 can lower blood pressure, says Aktiia A company making cuffless monitors for blood pressure says a significant and sustained reduction has been achieved for patients wearing the monitor 24/7. The device, made by Aktiia, measures blood pressure at optimal times throughout the day and night and was used in a study on hypertensive patients using a data set of more than […] September 12, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email